Abstract: The present invention provides compositions and methods for treating or preventing atrial fibrillation (AF). In particular, the present invention provides administration of muscarinic receptor antagonists (e.g., M2-selective muscarinic receptor blockers), administered alone or in combination with other therapeutic agents (e.g., beta-adrenergic receptor blockers) to treat and/or prevent atrial fibrillation.

Abstract: The invention relates generally to methods of detecting reactive oxygen species (ROS) in cardiac tissue and treatment modalities for ablating ROS-associated tissue in cardiac disease. The methods rely upon targeting ROS-associated cardiac tissue for ablation and/or gene therapy in a subject using analytical tools based upon a plurality of recorded atrial EGMs for a tissue to assess ROS content and underlying AF organization as a function of ROS blockade conditions.

Abstract: A method of targeting fibrosis or autonomic nerve tissue for ablation in a subject is described. The method includes at least the following steps. The method includes performing at least one EGM analysis of a plurality of recorded atrial EGMs for a tissue in a region suspected of having fibrosis or autonomic nerve tissue. With regard to targeting fibrosis for ablation, the method includes determining one or more correlations of at least one AF EGM characteristic to a region having fibrosis from the plurality of recorded atrial EGMs for the tissue and determining whether the tissue contains dense fibrosis that would preclude effective ablation of the analysis region of the tissue. With regard to targeting autonomic nerve for ablation, the method includes determining whether one or more significant changes in EGM characteristics with autonomic blockade exist that would indicate the need to perform ablation of the analysis region of the tissue.

Abstract: The disclosed methods pertain to diagnosing whether a non-ablative, gene therapy is needed for reducing AF fibrosis in a subject, and if so, methods of reducing AF fibrosis in a subject using gene therapy with a dominant negative TGF-? R2 cDNA expression vector. Kits and computer program products are also described, wherein the kits provide materials for diagnosing and treating AF fibrosis, and the computer program products include a computer readable medium having computer readable program code for monitoring the efficacy of therapeutic ablation of fibrosis in a subject using a gene therapy method.

Abstract: A method of targeting fibrosis or autonomic nerve tissue for ablation in a subject is provided. The method includes performing at least one EGM analysis of a plurality of recorded atrial EGMs for a tissue in a region suspected of having fibrosis or autonomic nerve tissue. With regard to targeting fibrosis for ablation, the method includes determining one or more correlations of at least one AF EGM characteristic to a region having fibrosis from the plurality of recorded atrial EGMs for the tissue and determining whether the tissue contains dense fibrosis that would preclude effective ablation of the analysis region of the tissue. With regard to targeting autonomic nerve for ablation, the method includes determining whether one or more significant changes in EGM characteristics with autonomic blockade exist that would indicate the need to perform ablation of the analysis region of the tissue.

Abstract: Disclosed herein are pharmaceutical compositions and methods for inhibiting oxidative stress in a subject having atrial or ventricular arrhythmias, ventricular failure or heart failure. The methods include administering an effective amount of a NOX2 inhibitor agent to the subject, wherein said administering is under conditions such that a level of oxidative stress in myocardial tissue is reduced or eliminated. The pharmaceutical compositions include a NOX2 inhibitor agent.

Abstract: The disclosed methods pertain to diagnosing whether a non-ablative, gene therapy is needed for reducing AF fibrosis in a subject, and if so, methods of reducing AF fibrosis in a subject using gene therapy with a dominant negative TGF-? R2 cDNA expression vector. Kits and computer program products are also described, wherein the kits provide materials for diagnosing and treating AF fibrosis, and the computer program products include a computer readable medium having computer readable program code for monitoring the efficacy of therapeutic ablation of fibrosis in a subject using a gene therapy method.

Abstract: The invention relates generally to methods of detecting reactive oxygen species (ROS) in cardiac tissue and treatment modalities for ablating ROS-associated tissue in cardiac disease. The methods rely upon targeting ROS-associated cardiac tissue for ablation and/or gene therapy in a subject using analytical tools based upon a plurality of recorded atrial EGMs for a tissue to assess ROS content and underlying AF organization as a function of ROS blockade conditions.

Abstract: A method of targeting fibrosis or autonomic nerve tissue for ablation in a subject is described. The method includes at least the following steps. The method includes performing at least one EGM analysis of a plurality of recorded atrial EGMs for a tissue in a region suspected of having fibrosis or autonomic nerve tissue. With regard to targeting fibrosis for ablation, the method includes determining one or more correlations of at least one AF EGM characteristic to a region having fibrosis from the plurality of recorded atrial EGMs for the tissue and determining whether the tissue contains dense fibrosis that would preclude effective ablation of the analysis region of the tissue. With regard to targeting autonomic nerve for ablation, the method includes determining whether one or more significant changes in EGM characteristics with autonomic blockade exist that would indicate the need to perform ablation of the analysis region of the tissue.

Abstract: The present invention provides compositions and methods for treating heart conditions. In particular, the present invention provides compositions and methods that block G protein coupled receptor mediated signaling for treating atrial fibrillation.

Abstract: The present invention provides compositions and methods for treating heart conditions. In particular, the present invention provides compositions and methods that block G protein coupled receptor mediated signaling for treating atrial fibrillation.

Abstract: A method, system, and computer program product for implementing automated worklists are provided. The method includes generating a worklist, which further includes retrieving a worklist template corresponding to the worklist and, via a first query, selecting a listing of members and attributes to be populated in the worklist, the attributes include a status indicator of an action item specified for each of the members of the worklist. The worklist generation also includes building a worklist member table with results of the first query and, via a second query, and using attributes of the worklist member table, identifying up-to-date values of one or more worklist member attributes, and outputting results of the second query to the worklist. The method also includes presenting the worklist to a corresponding assignee. For each of the members in the worklist, the status indicator is editable to update a status of the member.

Abstract: The present invention provides compositions and methods for treating heart conditions. In particular, the present invention provides compositions and methods that block G protein coupled receptor mediated signaling for treating atrial fibrillation.

Abstract: The present invention provides compositions and methods for treating or preventing atrial fibrillation (AF). In particular, the present invention provides administration of muscarinic receptor antagonists (e.g., M2-selective muscarinic receptor blockers), administered alone or in combination with other therapeutic agents (e.g., beta-adrenergic receptor blockers) to treat and/or prevent atrial fibrillation.

Abstract: The invention relates generally to systems and devices for material delivery, energy delivery, and/or monitoring electrophysiological activity, and method of use thereof. In particular, the present invention provides devices and systems, and methods of use thereof, configured to deliver therapeutic compositions, to provide electroporation and/or sonoporation to increase therapeutic efficiency, and to monitor electrophysiological activity, for example, before and after treatment.

Abstract: The invention relates generally to devices for material delivery, electroporation and monitoring electrophysiological activity. In particular, the present invention provides devices and systems configured to deliver therapeutic compositions, to provide electroporation to increase therapeutic efficiency, and to monitor electrophysiological activity, for example, before and after treatment.

Abstract: A method, system, and computer program product for implementing automated worklists are provided. The method includes generating a worklist, which further includes retrieving a worklist template corresponding to the worklist and, via a first query, selecting a listing of members and attributes to be populated in the worklist, the attributes include a status indicator of an action item specified for each of the members of the worklist. The worklist generation also includes building a worklist member table with results of the first query and, via a second query, and using attributes of the worklist member table, identifying up-to-date values of one or more worklist member attributes, and outputting results of the second query to the worklist. The method also includes presenting the worklist to a corresponding assignee. For each of the members in the worklist, the status indicator is editable to update a status of the member.

Abstract: The present invention provides compositions and methods for treating heart conditions. In particular, the present invention provides compositions and methods that block G protein coupled receptor mediated signaling for treating atrial fibrillation.